Oncology · Phase 2-3 · pulled 2026-11-06

Cervical cancer: trial sites and investigators

25 sites and 10 investigators from 148 completed and terminated Phase 2-3 trials of cervical cancer (last 12 years), plus 260 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Cervical cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Asan Medical Center Seoul, South Korea · 9 spellings merged	13 11 completed, 2 terminated	NCT05325866 NCT04221945 NCT04697628 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-01-28	8 NCT07216703 NCT06760819 NCT06023862 NCT06172478	90
2	Samsung Medical Center Seoul, South Korea · 7 spellings merged	13 10 completed, 3 terminated	NCT05325866 NCT04221945 NCT04697628 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-01-28	12 NCT07216703 NCT06760819 NCT06023862 NCT05086692	87
3	Seoul National University Hospital Seoul, South Korea · 6 spellings merged	13 10 completed, 3 terminated	NCT05325866 NCT04697628 NCT05007106 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-01-28	9 NCT06023862 NCT05086692 NCT06172478 NCT04977453	87
4	Severance Hospital, Yonsei University Health System Seoul, South Korea · 11 spellings merged	13 11 completed, 2 terminated	NCT05325866 NCT04221945 NCT04697628 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31	2026-01-28	10 NCT06760819 NCT06023862 NCT06172478 NCT04977453	92
5	University of Oklahoma Health Sciences Center Oklahoma City, United States · 11 spellings merged	13 10 completed, 3 terminated	NCT03108495 NCT03894215 NCT03635567 6 trials with titles NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04 NCT03476798 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium completed 2023-09-29 NCT02635360 Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer completed 2022-12-14 NCT03438396 A Trial of Tisotumab Vedotin in Cervical Cancer completed 2022-08-02	2025-08-22	10 NCT07061977 NCT05579366 NCT02465060 NCT02257528	88
6	MD Anderson Cancer Center Houston, United States · 9 spellings merged	12 7 completed, 5 terminated	NCT05325866 NCT03108495 NCT05572684 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors terminated 2025-04-30 Stop reason on the record: “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31 NCT05500508 Oral AMXT 1501 Dicaprate in Combination With IV DFMO terminated 2024-12-12 Stop reason on the record: “Required re-formulation of DFMO from IV to capsule to maintain safety” NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors terminated 2023-10-15 Stop reason on the record: “Sponsor Decision”	2026-01-28	15 NCT06760819 NCT05086692 NCT07109726 NCT06172478	83
7	Cliniques Universitaires Saint-Luc Brussels, Belgium · 6 spellings merged	11 9 completed, 2 terminated	NCT03786081 NCT05325866 NCT04697628 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT04405349 Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer completed 2023-11-24 NCT03257267 Study of Cemiplimab in Adults With Cervical Cancer completed 2023-04-20 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14	2026-03-19	4 NCT07216703 NCT06172478 NCT06330064 NCT04579380	81
8	Gustave Roussy Villejuif, France · 10 spellings merged	11 8 completed, 3 terminated	NCT05325866 NCT04697628 NCT03556839 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03612791 Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab completed 2025-05-13	2026-01-28	11 NCT06760819 NCT06172478 NCT06923761 NCT05581121	93
9	Dana-Farber Cancer Institute Boston, United States · 3 spellings merged	10 6 completed, 4 terminated	NCT03786081 NCT03108495 NCT03674567 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31 NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors terminated 2023-10-15 Stop reason on the record: “Sponsor Decision” NCT02865135 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer completed 2023-02-06 NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.”	2026-03-19	12 NCT05579366 NCT06760819 NCT02465060 NCT02257528	86
10	Augusta University Augusta, United States · 6 spellings merged	9 7 completed, 2 terminated	NCT03786081 NCT04697628 NCT03108495 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04 NCT04380805 A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer completed 2023-01-31	2026-03-19	5 NCT05579366 NCT02465060 NCT02466971 NCT04865887	83
11	Universitair Ziekenhuis Gent Ghent, Belgium · 7 spellings merged	9 6 completed, 3 terminated	NCT03786081 NCT05325866 NCT04697628 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT04646005 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy completed 2024-05-29 NCT04405349 Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer completed 2023-11-24 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14	2026-03-19	5 NCT07216703 NCT06172478 NCT06330064 NCT06459180	78
12	Sun Yat-sen University Cancer Center Guangzhou, China · 8 spellings merged	9 5 completed, 4 terminated	NCT04697628 NCT06022757 NCT05179239 6 trials with titles NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT06022757 Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) terminated 2025-01-13 Stop reason on the record: “Strategic decision by Sponsor.” NCT05179239 A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer terminated 2024-08-12 Stop reason on the record: “Sponsor develops strategy adjustment” NCT04799639 Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer completed 2024-06-24 NCT04341883 Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer completed 2024-04-26 NCT04974944 First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer terminated 2024-01-08 Stop reason on the record: “No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding discontinued, study terminated.”	2026-01-15	12 NCT06172478 NCT06993844 NCT04152499 NCT07797153	89
13	Centre Léon Bérard Lyon, France · 3 spellings merged	9 8 completed, 1 terminated	NCT03556839 NCT03108495 NCT05007106 6 trials with titles NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT04357873 Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations completed 2024-11-26 NCT03946358 Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) completed 2024-11-01	2025-08-31	9 NCT06172478 NCT06330064 NCT06923761 NCT05581121	97
14	Istituto Europeo di Oncologia Milan, Italy · 10 spellings merged	8 7 completed, 1 terminated	NCT03786081 NCT04221945 NCT03556839 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04	2026-03-19	5 NCT07216703 NCT06760819 NCT06459180 NCT05768139	94
15	Karmanos Cancer Institute Detroit, United States · 5 spellings merged	8 7 completed, 1 terminated	NCT04221945 NCT03108495 NCT05007106 6 trials with titles NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04 NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08 NCT03602079 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene completed 2022-01-12	2026-01-26	5 NCT05579366 NCT05086692 NCT05592626 NCT05768139	93
16	Moffitt Cancer Center Tampa, United States · 7 spellings merged	8 5 completed, 3 terminated	NCT03108495 NCT03894215 NCT03674567 6 trials with titles NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab completed 2024-12-31 NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04 NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.” NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08	2025-08-22	8 NCT07061977 NCT02465060 NCT02466971 NCT04579380	86
17	National Institutes of Health Clinical Center Bethesda, United States · 3 spellings merged	7 6 completed, 1 terminated	NCT04708470 NCT04287868 NCT04432597 6 trials with titles NCT04708470 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers completed 2026-08-21 NCT04287868 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies completed 2026-05-14 NCT04432597 HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers completed 2026-03-31 NCT02858310 E7 TCR T Cells for Human Papillomavirus-Associated Cancers completed 2025-07-02 NCT06865677 Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas terminated 2025-07-01 Stop reason on the record: “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.” NCT02487095 Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers completed 2024-12-26	2026-08-21	3 NCT05686226 NCT02465060 NCT05592626	96
18	Hospital Universitari Vall d'Hebron Barcelona, Spain · 9 spellings merged	7 5 completed, 2 terminated	NCT03786081 NCT04697628 NCT03556839 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT04646005 Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy completed 2024-05-29 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14	2026-03-19	6 NCT06172478 NCT06330064 NCT06923761 NCT06459180	87
19	Hospital Universitario 12 de Octubre Madrid, Spain · 6 spellings merged	7 6 completed, 1 terminated	NCT03786081 NCT04697628 NCT03556839 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14 NCT03438396 A Trial of Tisotumab Vedotin in Cervical Cancer completed 2022-08-02	2026-03-19	7 NCT07216703 NCT06172478 NCT06330064 NCT06459180	84
20	Memorial Sloan Kettering Cancer Center New York, United States · 5 spellings merged	7 5 completed, 2 terminated	NCT03786081 NCT05007106 NCT05012397 6 trials with titles NCT03786081 Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer terminated 2026-03-19 Stop reason on the record: “Sponsor has decided to stop the trial based on strategic decisions” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT05012397 Milademetan in Advanced/Metastatic Solid Tumors terminated 2023-10-15 Stop reason on the record: “Sponsor Decision” NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08 NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies completed 2021-11-09 NCT03180294 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer completed 2021-02-22	2026-03-19	6 NCT07061977 NCT02465060 NCT02257528 NCT06925724	81
21	Centre Oscar Lambret Lille, France · 4 spellings merged	7 5 completed, 2 terminated	NCT05325866 NCT03556839 NCT04016142 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT03556839 Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix completed 2025-08-31 NCT04016142 Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer terminated 2025-01-31 Stop reason on the record: “The study is discontinued because of recruitment failure, and for strategic reason (competitive trials with immunotherapy)” NCT04357873 Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations completed 2024-11-26 NCT04205799 Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure completed 2023-01-15 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14	2026-01-28	4 NCT06760819 NCT05581121 NCT06715241 NCT05078047	91
22	Princess Margaret Cancer Centre Toronto, Canada · 6 spellings merged	7 6 completed, 1 terminated	NCT05325866 NCT04221945 NCT04697628 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03635567 Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) completed 2024-06-04 NCT03257267 Study of Cemiplimab in Adults With Cervical Cancer completed 2023-04-20	2026-01-28	8 NCT07216703 NCT06760819 NCT06172478 NCT04152499	90
23	Chongqing Cancer Hospital Chongqing, China · 5 spellings merged	7 7 completed, 0 terminated	NCT04221945 NCT04697628 NCT05383482 6 trials with titles NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05383482 Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 completed 2024-07-18 NCT04870177 Study of AK112 in the Treatment of Advanced Gynecological Tumors completed 2024-05-10 NCT04693234 AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer completed 2023-08-31 NCT04246489 Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer completed 2022-12-14	2026-01-26	7 NCT05579366 NCT04152499 NCT06459180 NCT06799637	94
24	Mackay Memorial Hospital Taipei, Taiwan · 7 spellings merged	7 6 completed, 1 terminated	NCT04221945 NCT04697628 NCT05007106 6 trials with titles NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT04697628 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer completed 2026-01-15 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT04300647 A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer completed 2025-02-24 NCT04693234 AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer completed 2023-08-31	2026-01-26	2 NCT07216703 NCT06172478	85
25	Ohio State University Comprehensive Cancer Center Columbus, United States · 12 spellings merged	7 4 completed, 3 terminated	NCT04221945 NCT03108495 NCT03894215 6 trials with titles NCT04221945 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) completed 2026-01-26 NCT03108495 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma terminated 2025-08-22 Stop reason on the record: “After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.” NCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer terminated 2025-03-26 Stop reason on the record: “Sponsor strategic decision” NCT04171700 A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes terminated 2022-07-15 Stop reason on the record: “The study was terminated due to a change in development priorities.” NCT03104699 A Study of AGEN2034 in Advanced Tumors and Cervical Cancer completed 2022-06-15 NCT03989115 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC completed 2022-02-08	2026-01-26	11 NCT07216703 NCT07061977 NCT05579366 NCT02465060	85

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Cervical cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Charalampos Floudas National Cancer Institute (NCI)	3	NCT04432597 NCT04287868 NCT02866006	No paper matched at High or Medium confidence
2	Li Zhang botanic physician	3	NCT06022757 NCT04188860 NCT04188847	No paper matched at High or Medium confidence
3	Lung-Ji Chang Shenzhen Geno-Immune Medical Institute	2	NCT03356795 NCT03362619	No paper matched at High or Medium confidence
4	Kevin C Conlon National Cancer Institute (NCI)	2	NCT06865677 NCT02394652	No paper matched at High or Medium confidence
5	Jihong Liu Sun Yat-sen University	2	NCT04799639 NCT03427411	PMID 42976708 Ecotoxicology and environmental safety, 2026 · High match PMID 42936392 iScience, 2026 · High match PMID 42922355 Journal of gynecologic oncology, 2026 · High match
6	Qi Zhou Chongqing University Cancer Hospital	2	NCT04870177 NCT06226350	PMID 42631593 Journal of visualized experiments : JoVE, 2026 · Medium match PMID 42482776 Frontiers in pharmacology, 2026 · High match
7	Xin Huang Sun Yat-Sen University Cancer Center	2	NCT04974944 NCT04651127	PMID 42908142 Journal of clinical ultrasound : JCU, 2026 · High match PMID 42755801 Frontiers in oncology, 2026 · High match PMID 42679896 Tumour virus research, 2026 · High match
8	Jun Zhang Xiamen University	2	NCT04782895 NCT03935204	No paper matched at High or Medium confidence
9	Manoj Pandey Banaras Hindu University	2	NCT05384366 NCT03367871	PMID 42217258 Gynecologic oncology, 2026 · High match
10	Keiichi Fujiwara Saitama Medical University International Medical Center	2	NCT03913741 NCT02247232	PMID 41644383 International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2026 · High match PMID 40075617 Cancers, 2025 · Medium match PMID 40010135 European journal of cancer (Oxford, England : 1990), 2025 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.